Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Src activation plays a crucial role in cancer progression, particularly in lung cancer, through its interplay with the Epidermal Growth Factor Receptor (EGFR).
• Inhibition of Src signaling pathways can repress EGFR-regulated pathways, making Src a significant molecular target for anti-cancer drug development.

Purpose of the Study:

• To identify compounds targeting Src to inhibit lung cancer tumorigenesis and metastasis.
• To investigate the molecular mechanisms underlying the action of these compounds.

Main Methods:

• Molecular docking was employed to screen the National Cancer Institute (NCI) compound dataset for potential Src inhibitors.
• In vitro and in vivo assays were conducted to evaluate the efficacy of selected compounds, including rhodomycin A, on cancer cell behavior and tumor growth.

Main Results:

• Rhodomycin A demonstrated potent dose-dependent inhibition of Src activity and expression, along with associated proteins like EGFR, STAT3, and FAK.
• Rhodomycin A significantly suppressed lung cancer cell proliferation, migration, invasion, and clonogenicity in vitro, and reduced tumor growth in vivo.
• Rhodomycin A resensitized gefitinib-resistant lung adenocarcinoma cells to gefitinib, suggesting a synergistic effect.

Conclusions:

• Rhodomycin A effectively inhibits lung cancer progression by suppressing Src-related signaling pathways, including PI3K, JNK, Paxillin, and p130cas.
• These findings support the development of rhodomycin A as a potential anti-cancer drug for lung cancer treatment, possibly in combination therapy.